BioSpace News Archive

Drug Development

Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies

Kura Oncology, Inc. today reported preclinical data supporting the potential use of farnesyl transferase inhibitors (FTIs) to treat various types of solid tumors in combination with targeted therapies, including KRASG12C inhibitors and anti-angiogenic tyrosine kinase inhibitors (TKIs).

April 17, 2023

·

6 min read

Business

Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that P. Roy Vagelos, M.D., will retire from his role as Chair of the Company’s Board of Directors and will not stand for reelection at the Company’s 2023 Annual Meeting of Shareholders.

April 17, 2023

·

3 min read

Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope

Radiopharm Theranostics is pleased to announce an agreement with TerThera to supply the Company with Terbium-161 (Tb-161).

April 17, 2023

·

4 min read

Genetown

Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity

Phio Pharmaceuticals Corp. today announced that in vivo data from a hepatocellular carcinoma model provides insight into the mechanism by which locally administered mouse-targeted PH-762 (mPH-762) exerts systemic anti-tumor efficacy (“abscopal effect”).

April 17, 2023

·

4 min read

Biotech Bay

PhenomeX Launches the Opto® T Cell Profiling Workflow

PhenomeX Inc. today announced the launch of its Opto® T Cell Profiling workflow enabling increased efficiency and high precision T cell characterization for development of efficacious immunotherapies.

April 17, 2023

·

3 min read

Business

KBI Biopharma and Selexis SA Appoint J.D. Mowery as CEO

KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies, today announced the appointment of J.D. Mowery as Chief Executive Officer (CEO).

April 17, 2023

·

3 min read

FDA

Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer

Agenus Inc. has been granted Fast Track Designation from the US Food and Drug Administration (FDA) for the investigation of the combination of botensilimab (AGEN1181) and balstilimab (AGEN2034).

April 17, 2023

·

5 min read

Drug Development

Sporos BioDiscovery Presents Preclinical Data on Next-Generation TEAD Inhibitor, SPR1-0117, at the American Association for Cancer Research (AACR) Annual Meeting 2023

Sporos BioDiscovery, Inc. presented preclinical data for its lead candidate, SPR1-0117, a next-generation TEAD inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

April 17, 2023

·

6 min read

Drug Development

Parthenon Therapeutics Announces Data at the American Association for Cancer Research (AACR) Annual Meeting 2023 on Prevalence of Immune Exclusion in Solid Tumors to Support Phase 1 Clinical Trial of PRTH-101

Parthenon Therapeutics today presented data at the AACR Annual Meeting 2023, on the high prevalence of immune exclusion in select solid tumor types.

April 17, 2023

·

4 min read

FDA

HanchorBio Announces US IND Clearance for the Multi-Regional Clinical Trial of HCB101 to Treat Solid and Hematological Malignancies

HanchorBio Inc. announced today that the US. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a multi-regional clinical trial of its independently-developed novel drug candidate, HCB101.

April 17, 2023

·

4 min read